Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010

In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, ...

Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
Zacks Investment Research on MSN

MRNA stock jumps on global submissions seeking nod for flu vaccine

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 ...
Uticaod

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...

An ER doctor used 2 factors to decide on Moderna instead of Pfizer for vaccinating his toddler

Both vaccines work. But Pfizer requires a longer waiting period before the vaccine kicks in, while Moderna has stronger side effects.
TipRanks on MSN

Moderna announces regulatory submissions for seasonal influenza vaccine

Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...

Moderna, Inc.: Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda ...